论文部分内容阅读
为了探讨游离前列腺特异抗原(fPSA)与总前列腺特异抗原(tPSA)比率对前列腺癌的诊断价值,采用酶联免疫方法分别测定41例前列腺癌病人,36例前列腺增生(BPH)病人血清tPSA、fPSA,并计算出fPSA/tPSA比率。tPSA界限值为4μg/L时,敏感度,特异度,准确度分别为82.9%,60.0%,72.4%;fPSA/tPSA界限值定为17.0%时,敏感度,特异度,准确度分别为87.8%,93.0%,84.2%。结果表明:fPSA/tPSA在保持敏感度的同时,可显著地提高特异度,能更有效地诊断前列腺癌
To investigate the diagnostic value of free prostate-specific antigen (fPSA) and total prostatespecific antigen (tPSA) in prostate cancer, enzyme-linked immunosorbent assay was used to detect 41 patients with prostate cancer and 36 patients with benign prostatic hyperplasia (BPH) Serum t-PSA, f-PSA, and calculate the ratio of f-PSA / t-PSA. The sensitivity, specificity and accuracy were 82.9%, 60.0% and 72.4% respectively when the threshold value of TSPSA was 4μg / L; the threshold value of fPSA / tPSA was 17.0 %, The sensitivity, specificity and accuracy were 87.8%, 93.0% and 84.2% respectively. The results showed that: fPSA / tPSA while maintaining sensitivity, can significantly improve the specificity, can be more effective in the diagnosis of prostate cancer